Irrigation solution and method for inhibition of pain, inflammation and spasm

围术期用于抑制伤口部位各种疼痛、炎症以及痉挛过程的方法和溶液。该溶液包括多种疼痛/炎症抑制药物以及痉挛抑制药物，用生理性基础溶液例如生理盐水或加入乳酸盐的林格氏溶液配制成烯浓度溶液。根据用途的不同，加到该溶液中的疼痛/炎症抑制药物包括以下15类：(1)5-羟色胺受体拮抗剂；(2)5-羟色胺受体激动剂；(3)组织胺受体拮抗剂；(4)舒缓激肽受体拮抗剂；(5)激肽释放酶抑制剂；(6)速激肽受体拮抗剂，包括神经激肽1和神经激肽2受体亚型拮抗剂；(7)降钙素基因相关肽(CGRP)受体拮抗剂；(8)白细胞介素受体拮抗剂；(9)作用于花生四烯酸代谢物合成通路的酶的抑制剂，包括：(a)磷脂酶抑制剂，包括PLA#-[2]异形酶和PLCr异形酶抑制剂，(b)环氧合酶抑制剂以及(c)脂氧酶抑制剂；(10)前列腺素类受体拮抗剂包括类花生酸EP-1和EP-2受体亚型拮抗剂以及凝血�烷受体亚型拮抗剂；(11)白细胞三烯受体拮抗剂，包括白细胞三烯B#-[4]和D#-[4]受体亚型拮抗剂；(12)类阿片受体激动剂，包括mu-阿片，delta-阿片和kappa-阿片受体亚型激动剂；(13)嘌呤受体激动剂和拮抗剂，包括P#-[2X]受体拮抗剂和P#-[2Y]受体激动剂；(14)三磷酸腺苷(ATP)-敏感的钾通道开放剂；以及(15)钙通道拮抗剂。还能作为抗痉挛药的适宜的抗痛和抗炎药物包括5-羟色胺受体拮抗剂，速激肽受体拮抗剂，ATP-敏感的钾通道开放剂以及钙通道拮抗剂。根据其抗痉挛性质这一特性而可以用于该溶液的其他药物包括内皮素受体拮抗剂和一氧化氮供体(酶激活剂)。本溶液用于手术或介入性操作期间连续冲洗伤口，以抢先抑制疼痛和炎症，以及血管和平滑肌痉挛，而避免与这些药物大剂量口服，肌肉内，或静脉内应用相关的不良副反应。本溶液可用于关节内窥镜检查，血管内和泌尿道操作，以及应用于烧伤，和手术过程中及手术后应用于手术伤口。 A method and solution for perioperatively inhibiting a variety of pain and inflammation and spasm processes at a wound. The solution includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic base, such as saline or lactated Ringer's solution. Depending on the application, the pain and inflammation agents included in the solution may include: (1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists: (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin 1 and neurokinin 2 receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists; (9) inhibitors of enzymes active in the synthetic pathway for arachadonic acid metabolites, including (a) phospholipase inhibitors, including PLA 2 isoform and PLC³ isoform inhibitors, (b) cyclooxygenase inhibitors, and (c) lipooxygenase inhibitors; (10) prostanoid receptor antagonists including eicosanoid EP-1 and EP-2 receptor subtype antagonists and thromboxane receptor subtype antagonists; (11) leukotriene receptor antagonists including leukotriene B 4 and D 4 receptor subtype antagonists; (12) opioid receptor agonists, including mu-opiate, delta-opiate, and kappa-opiate receptor subtype agonists; (13) purinoceptor agonists and antagonists including P 2X receptor antagonists and P 2Y receptor agonists; (14) adenosine triphosphate (ATP) sensitive potassium channel openers; and (15) calcium channel antagonists. Suitable anti-inflammatory/anti-pain agents which also act as anti-spasm agents